←
Michael Fisch MD MPH18,910 posts
Michael Fisch MD MPH avatar

Michael Fisch MD MPH

@fischmd

Carelon (Medical Director), MD Anderson Cancer Ctr (Clinical Professor). Med Onc, Internal Med, Palliative Care

◷ Joined February 2011▧ 500 Photos and videos
ASCO avatar
⟳ Michael Fisch MD MPH retweeted
ASCO@ASCO·Oct 16

Read a short #ASCODailyNews profile on Dr. @Areejmd and her emphasis on meeting the needs of patients with blood cancers and their caregivers: bit.ly/4ypiCh1

ASCO@ASCOOct 16

Congratulations to @Areejmd, FASCO, winner of the Joseph V. Simone Quality Care Award! 🏆This honor recognizes her multiple, significant & enduring contributions to the quality and safety of cancer care. Thank you for your leadership! #ASCOQLTY26 Session: bit.ly/4zqN0aV

Post attachmentPost attachment
Daniel V. Araujo avatar
⟳ Michael Fisch MD MPH retweeted
Daniel V. Araujo@DVAraujoMD·May 28

A really thought-provoking study at #ASCO26 (Abstr 4512, Clinical Science Symposium): decision regret after adjuvant pembrolizumab in RCC. 🔹 The question Do patients regret receiving adjuvant pembro — and if so, is it driven by long-term toxicity that CTCAE grading doesn't adequately reflect? They built a patient co-designed tool focused on long-term toxicity. 🔹 The study 104 RCC pts post-adjuvant pembro across 3 London centres, median f/u 30 mo. Pts completed the Ottawa Decision Regret Scale alongside their own rating of irAEs as life-changing, significant, or non-significant. 🔹 What they found 28% rated their toxicity as significant and 11% as life-changing — but these ratings did NOT correlate with CTCAE grade (a third of G1–2 events were rated significant), and regret was identical for G1–2 vs G3–4 irAEs. Regret was driven by patient-perceived long-term toxicity, especially permanent endocrine and MSK irAEs — and not by disease recurrence (only 1/14 who relapsed expressed regret). Lower baseline expectations of toxicity → more regret. 🔹 My take Striking that >1 in 4 reported significant and >1 in 10 life-changing toxicity. What concerns me most isn't that CTCAE missed these events — it's that the grade didn't correlate with how significant patients found them, nor with regret at all. That deviates from the very purpose of grading. The hard part: a regret analysis is tough to contextualize when the alternative, no treatment, risks recurrence — arguably worse than a long-term toxicity. Adjuvant therapy is challenging by nature: most patients are either cured already or destined to recur regardless — we expose everyone to toxicity to benefit a minority. We urgently need biomarkers to find the few who truly benefit. This slide from @Prof_IanD says it all 👇 Looking forward to seeing the presentation! 🔗 asco.org/abstracts-presentat… #kcsm #ASCO26 @BethN01 @tompowles1

Post attachment
Laura Esfeller avatar
⟳ Michael Fisch MD MPH retweeted
Laura Esfeller@LauraEsfeller·Apr 30

Fascinating, important convo on the role of APPs in #clinicaltrial research & patient access to trials. APPs have been an important part of my cancer experience, including a PA who advocated to get me scanned the night I was diagnosed. Let’s break down the barriers! #SWOGSpring26

Post attachment
Young Kwang Chae, MD, MPH, MBA avatar
⟳ Michael Fisch MD MPH retweeted
Young Kwang Chae, MD, MPH, MBA@youngkwangchae·May 1

Highlights from @SWOG’s high-impact oncology trials & future vision 🧬 by our new #SWOG co-chairs, @PrimoLaraMD @DrDawnHershman ✅ S1609 DART: 53 rare cancer cohorts, one basket study ✅ ctDNA clearance predicts outcomes in NSCLC And so many more! 🔭 SWOG’s next era: public-powered research tackling what industry can’t 🚀 • Fewer phase I → more definitive phase III trials 📊 • Pragmatic, efficient studies (⅓ of portfolio) ⚡ • Multi-modality strategies & treatment de-escalation 🎯 • AI + real-world data accelerating innovation 🤖📈 @SupportingSWOG #Oncology #ClinicalTrials #CancerResearch

Post attachmentPost attachmentPost attachmentPost attachment
JAMA Oncology avatar
⟳ Michael Fisch MD MPH retweeted
JAMA Oncology@JAMAOnc·4 Aug 2025

Scheduled lorazepam, alone or combined with haloperidol, more effectively reduced agitation and restlessness in palliative care patients with advanced cancer and delirium than haloperidol or placebo. ja.ma/3IYTzwh @drdavidhui

Post attachment
Dr. Dominic Ng avatar
⟳ Michael Fisch MD MPH retweeted
Dr. Dominic Ng@DrDominicNg·30 Jun 2025

Microsoft claims their new AI framework diagnoses 4x better than doctors. I'm a medical doctor and I actually read the paper. Here's my perspective on why this is both impressive AND misleading ... 🧵

Post attachment
Anirban Maitra avatar
⟳ Michael Fisch MD MPH retweeted
Anirban Maitra@Aiims1742·29 Jun 2025

Happy Birthday to MD Anderson! As @DGlaucomflecken recently told us, growing up as a child in Deer Park, Houston, he simply couldn’t figure out why the good “Dr. Anderson” had the “MD” before his name. 😆 P.S. - it’s Monroe Dunaway

Today in 1873, cotton industrialist and philanthropist MD Anderson is born. @MDAndersonNews

Dr Joseph McCollom DO avatar
⟳ Michael Fisch MD MPH retweeted
Dr Joseph McCollom DO@realbowtiedoc·24 Jun 2025

Love this quote from @jrgralow. We can't view #AI as a physician replacement, nor can we reduce #efficiency gained by #AI as turning #docs into a cog ⚙️ Thanks @ravi_b_parikh for advocating for protections both for now and the future. @ca_chung @dougflora2 @HundalJasmin

Post attachment

#AI has improved my efficiency in clinic. But in other industries, AI in the name of efficiency turns employees into "Quantified Workers". #Doctors aren't immune. In @NEJM,@CohenProf @iajunwa & I propose a Clinician Bill of Rights to prioritize autonomy during the AI revolution

Post attachment
Ravi B. Parikh avatar
⟳ Michael Fisch MD MPH retweeted
Ravi B. Parikh@ravi_b_parikh·19 Jun 2025

#AI has improved my efficiency in clinic. But in other industries, AI in the name of efficiency turns employees into "Quantified Workers". #Doctors aren't immune. In @NEJM,@CohenProf @iajunwa & I propose a Clinician Bill of Rights to prioritize autonomy during the AI revolution

Post attachment

New article in @NEJM by @CohenProf @iajunwa & @ravi_b_parikh explores increased risk that AI will be used to surveil and monitor health care workers nejm.org/doi/full/10.1056/NE… @Harvard @HACLab_ @WinshipatEmory @emorylaw @emory @CeBIL_Center @novonordiskfond

Post attachment
Mark Lewis, MD, FASCO avatar
⟳ Michael Fisch MD MPH retweeted
Mark Lewis, MD, FASCO@marklewismd·16 Jun 2025

This painting (Fildes’ The Doctor) is like a Rorschach test of how I’m feeling as a physician Often I see the virtue of presence, where we literally cultivate our bedside manner Other times I discern the intractable progression of disease we are powerless to halt It’s both

Post attachment
Dan O'Neill avatar
⟳ Michael Fisch MD MPH retweeted
Dan O'Neill@dp_oneill·15 Jun 2025

Two reasons for caution in our expectations for how AI may affect administrative overhead in healthcare are: - Most areas of admin friction were readily addressable through the technology of 10-20 years ago, but remain with us - Most problems are not computational at their core